Group sequential designs for negative binomial outcomes

Count data and recurrent events in clinical trials, such as the number of lesions in magnetic resonance imaging in multiple sclerosis, the number of relapses in multiple sclerosis, the number of hospitalizations in heart failure, and the number of exacerbations in asthma or in chronic obstructive pulmonary disease (COPD) are often modeled by negative binomial distributions. In this manuscript, we study planning and analyzing clinical trials with group sequential designs for negative binomial outcomes. We propose a group sequential testing procedure for negative binomial outcomes based on Wald statistics using maximum likelihood estimators. The asymptotic distribution of the proposed group sequential test statistics is derived. The finite sample size properties of the proposed group sequential test for negative binomial outcomes and the methods for planning the respective clinical trials are assessed in a simulation study. The simulation scenarios are motivated by clinical trials in chronic heart failure and relapsing multiple sclerosis, which cover a wide range of practically relevant settings. Our research assures that the asymptotic normal theory of group sequential designs can be applied to negative binomial outcomes when the hypotheses are tested using Wald statistics and maximum likelihood estimators. We also propose two methods, one based on Student’s t-distribution and one based on resampling, to improve type I error rate control in small samples. The statistical methods studied in this manuscript are implemented in the R package gscounts, which is available for download on the Comprehensive R Archive Network (CRAN).

[1]  Cyrus Mehta,et al.  Optimizing Trial Design: Sequential, Adaptive, and Enrichment Strategies , 2009, Circulation.

[2]  James M. Robins,et al.  Semiparametric Efficiency and its Implication on the Design and Analysis of Group-Sequential Studies , 1997 .

[3]  S. Solomon,et al.  Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved , 2014, European journal of heart failure.

[4]  Bart Spiessens,et al.  Adjusted significance levels for subgroup analyses in clinical trials. , 2010, Contemporary clinical trials.

[5]  J. McMurray,et al.  Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations , 2012, Circulation.

[6]  J A Anderson,et al.  Methods for therapeutic trials in COPD: lessons from the TORCH trial , 2009, European Respiratory Journal.

[7]  Jeroen J. Bax,et al.  Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases , 2017, European journal of heart failure.

[8]  S. Pocock,et al.  Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). , 2014, JACC. Heart failure.

[9]  Meinhard Kieser,et al.  Assessment of clinical relevance by considering point estimates and associated confidence intervals , 2005 .

[10]  J. Udelson.  Heart failure with preserved ejection fraction. , 2011, Circulation.

[11]  Donald R Hoover,et al.  A Procedure for Group Sequential Comparative Poisson Trials , 2007, Journal of biopharmaceutical statistics.

[12]  Richard J. Cook,et al.  Incorporating Surrogate Endpoints into Group Sequential Trials , 1996 .

[13]  Christopher Jennison,et al.  Bootstrap Tests and Confidence Intervals for a Hazard Ratio When the Number of Observed Failures is Small, With Applications to Group Sequential Survival Studies , 1992 .

[14]  F. Barkhof,et al.  Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials , 1999, Journal of the Neurological Sciences.

[15]  W. Jiang.  Group sequential procedures for repeated events data with frailty. , 1999, Journal of biopharmaceutical statistics.

[16]  R J Cook,et al.  Interim monitoring of longitudinal comparative studies with recurrent event responses. , 1996, Biometrics.

[17]  Jeffrey A. Cohen,et al.  Multiple sclerosis therapeutics, fourth edition , 2011 .

[18]  Sample size determination for matched-pair equivalence trials using rate ratio. , 2007, Biostatistics.

[19]  Bernhard Hemmer,et al.  Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study , 2013, The Lancet Neurology.

[20]  S. Pocock.  Group sequential methods in the design and analysis of clinical trials , 1977 .

[21]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[22]  J. Lawless.  Negative binomial and mixed Poisson regression , 1987 .

[23]  Axel Munk,et al.  Design and analysis of three‐arm trials with negative binomially distributed endpoints , 2016, Statistics in medicine.

[24]  C. Farrington,et al.  Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. , 1990, Statistics in medicine.

[25]  P. Gallo,et al.  Alternative Views On Setting Clinical Trial Futility Criteria , 2014, Journal of biopharmaceutical statistics.

[26]  Heinz Schmidli,et al.  Modelling and sample size reestimation for longitudinal count data with incomplete follow up , 2019, Statistical methods in medical research.

[27]  D O Scharfstein,et al.  The use of simulation and bootstrap in information-based group sequential studies. , 1998, Statistics in medicine.

[28]  Eric R. Ziegel,et al.  Generalized Linear Models , 2002, Technometrics.

[29]  Guideline on clinical investigation of medicinal products for the treatment of acute heart failure , 2015 .

[30]  J. Marsal,et al.  Effect of Clopidogrel and Aspirin vs Aspirin Alone on Migraine Headaches After Transcatheter Atrial Septal Defect Closure: The CANOA Randomized Clinical Trial. , 2015, JAMA.

[31]  J A Anderson,et al.  Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited , 2008, European Respiratory Journal.

[32]  Anastasios A. Tsiatis,et al.  Flexible Sample Size Considerations Using Information-Based Interim Monitoring , 2001 .

[33]  Axel Munk,et al.  A studentized permutation test for three‐arm trials in the ‘gold standard’ design , 2016, Statistics in medicine.

[34]  Juerg Schwitter,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[35]  Tim Friede,et al.  Clinical trials with nested subgroups: Analysis, sample size determination and internal pilot studies , 2018, Statistical methods in medical research.

[36]  O. Keene,et al.  Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study , 2007, Pharmaceutical statistics.

[37]  Violations of the independent increment assumption when using generalized estimating equation in longitudinal group sequential trials , 2014, Statistics in medicine.

[38]  Richard J. Cook,et al.  The Statistical Analysis of Recurrent Events , 2007 .

[39]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[40]  M. Landray,et al.  Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. , 2016, European heart journal.

[41]  Heinz Schmidli,et al.  Blinded sample size reestimation with count data: Methods and applications in multiple sclerosis , 2010, Statistics in medicine.

[42]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[43]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[44]  J. Fleg,et al.  Heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[45]  D. Spiegelhalter,et al.  Monitoring of large randomised clinical trials: a new approach with Bayesian methods , 2001, The Lancet.

[46]  Jeffrey A. Cohen,et al.  Multiple Sclerosis Therapeutics , 1999 .

[47]  Roland Fisch,et al.  Bayesian Design of Proof-of-Concept Trials , 2015, Therapeutic innovation & regulatory science.

[48]  Michael A. Proschan,et al.  Effects of assumption violations on type I error rate in group sequential monitoring , 1992 .

[49]  T Friede,et al.  Blinded Sample Size Reestimation with Negative Binomial Counts in Superiority and Non-inferiority Trials , 2010, Methods of Information in Medicine.

[50]  Gernot Wassmer,et al.  Group Sequential and Confirmatory Adaptive Designs in Clinical Trials , 2016 .

[51]  A. Tselis.  Multiple sclerosis therapeutics J.A. Cohen , 2012, Journal of the Neurological Sciences.

[52]  G. Wassmer,et al.  Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker , 2018, Statistical methods in medical research.

[53]  A. So,et al.  Extended Report , 2022 .

[54]  Heinz Schmidli,et al.  A practical guide to Bayesian group sequential designs , 2014, Pharmaceutical statistics.

[55]  G. Yi,et al.  Sequential Testing with Recurrent Events over Multiple Treatment Periods , 2010 .

[56]  H Merabet,et al.  The design and analysis of sequential clinical trials , 2013 .

[57]  Inmaculada B. Aban,et al.  Inferences and power analysis concerning two negative binomial distributions with an application to MRI lesion counts data , 2009, Comput. Stat. Data Anal..

[58]  Christopher Jennison,et al.  Group Sequential Analysis Incorporating Covariate Information , 1997 .